INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 454m ago
HOUSE PTR54m ago
SEC 13F54m ago
ROBINHOOD CHAIN54m ago
Public company

ALLOAllogene Therapeutics, Inc.

CIK 0001737287

EDGAR filingsOpen in network
Disclosed transactions5
Buys / sells0 / 5
Max Insider Score25
Connections5with evidence

ALLO · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
21
PM
Parker Geoffrey M.CHIEF FINANCIAL OFFICER
ALLOAllogene Therapeutics, Inc.
Open-market sale
SELL$49K
36.3K sh
Oct 21, 2026Oct 23, 2026
traded Oct 21, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Parker Geoffrey M.CHIEF FINANCIAL OFFICER · Oct 23, 2026
  • ← Insider ofevidence
    Yoshiyama AnnieSVP, Finance · Apr 23, 2026
  • ← Insider ofevidence
    Beneski Benjamin MachinasSVP, Chief Technical Officer · Mar 4, 2026
25
YA
Yoshiyama AnnieSVP, Finance
ALLOAllogene Therapeutics, Inc.
Open-market sale
SELL
$22K
9,586 sh
Apr 21, 2026
Apr 23, 2026
traded Apr 21, 2026
+2d
SEC FORM 4

Evidence

17
BM
Beneski Benjamin MachinasSVP, Chief Technical Officer
ALLOAllogene Therapeutics, Inc.
Open-market sale
SELL$7,168
2,867 sh
Mar 31, 2026Apr 2, 2026
traded Mar 31, 2026
+2dSEC FORM 4

Evidence

21
BM
Beneski Benjamin MachinasSVP, Chief Technical Officer
ALLOAllogene Therapeutics, Inc.
Open-market sale
SELL$19K
7,132 sh
Mar 2, 2026Mar 4, 2026
traded Mar 2, 2026
+2dSEC FORM 4

Evidence

21
RZ
Roberts ZacharyEVP of R&D
ALLOAllogene Therapeutics, Inc.
Open-market sale
SELL$41K
26.3K sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Roberts ZacharyEVP of R&D · Jan 23, 2026